Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ANNX · Why this verdict
Why Annexon (ANNX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Insider buying has been notable, with company insiders purchasing roughly $3.4 million in shares over the past 90 days, a meaningful vote of confidence relative to market value. Insider breakdown | Insider buying should continue, or at least the net-bullish insider signal should persist, over the next 12 months. | →Stable |
| CounterInsider buying at biotech companies can be driven by option exercises or compensation-related purchases rather than a pure conviction bet, and does not guarantee clinical or commercial success. | ||
Business quality sits well below the minimum threshold required for a position, reflecting persistent cash burn and the absence of a competitive moat. Bear case | The quality score should recover above the 4.0 floor over the next 12 months as the cash-burn profile improves. | →Stable |
| CounterCash burn without a moat is common and often expected for a clinical-stage biotechnology name still pre-commercial, so the quality gap may persist by design rather than reflect distress. | ||
The chart has confirmed a bullish breakout, with a golden cross, shares trading above all major moving averages, and a bullish MACD reading. Chart pattern detection | The breakout should hold, with shares continuing to trade above their key moving averages over the next 12 months. | →Stable |
| CounterA breakout confirmed alongside an RSI near 69 already flirts with overbought territory, raising the risk of a near-term pullback that could quickly invalidate the setup. | ||
Short interest is elevated at 17% of float and options positioning skews defensive with a put/call ratio of 1.60, indicating meaningful bearish positioning against the stock. Key risks | Short interest and the put/call ratio should decline toward more typical levels over the next 12 months if the bullish breakout is validated by fundamentals. | →Stable |
| CounterElevated short interest combined with a confirmed breakout can also set up a short squeeze that mechanically drives the stock higher regardless of fundamentals, distorting the read on that positioning. | ||
Recent earnings execution has been strong, with three beats against one miss over the last four quarters, supporting an analyst-implied upside near 140%. Catalyst breakdown | The beat rate should hold at 75% or better over the next 12 months, supporting continued upward analyst target revisions. | →Stable |
| CounterLight analyst coverage means both the beat-rate signal and the upside estimate rest on a small sample and could swing sharply on a single revision. | ||
Insider buying has been notable, with company insiders purchasing roughly $3.4 million in shares over the past 90 days, a meaningful vote of confidence relative to market value.
→StableInsider breakdown
- Expectation
- Insider buying should continue, or at least the net-bullish insider signal should persist, over the next 12 months.
CounterInsider buying at biotech companies can be driven by option exercises or compensation-related purchases rather than a pure conviction bet, and does not guarantee clinical or commercial success.
Business quality sits well below the minimum threshold required for a position, reflecting persistent cash burn and the absence of a competitive moat.
→StableBear case
- Expectation
- The quality score should recover above the 4.0 floor over the next 12 months as the cash-burn profile improves.
CounterCash burn without a moat is common and often expected for a clinical-stage biotechnology name still pre-commercial, so the quality gap may persist by design rather than reflect distress.
The chart has confirmed a bullish breakout, with a golden cross, shares trading above all major moving averages, and a bullish MACD reading.
→StableChart pattern detection
- Expectation
- The breakout should hold, with shares continuing to trade above their key moving averages over the next 12 months.
CounterA breakout confirmed alongside an RSI near 69 already flirts with overbought territory, raising the risk of a near-term pullback that could quickly invalidate the setup.
Short interest is elevated at 17% of float and options positioning skews defensive with a put/call ratio of 1.60, indicating meaningful bearish positioning against the stock.
→StableKey risks
- Expectation
- Short interest and the put/call ratio should decline toward more typical levels over the next 12 months if the bullish breakout is validated by fundamentals.
CounterElevated short interest combined with a confirmed breakout can also set up a short squeeze that mechanically drives the stock higher regardless of fundamentals, distorting the read on that positioning.
Recent earnings execution has been strong, with three beats against one miss over the last four quarters, supporting an analyst-implied upside near 140%.
→StableCatalyst breakdown
- Expectation
- The beat rate should hold at 75% or better over the next 12 months, supporting continued upward analyst target revisions.
CounterLight analyst coverage means both the beat-rate signal and the upside estimate rest on a small sample and could swing sharply on a single revision.
TrendMatrix Research · core thesis
Engine thesis — one sentence
ANNX combines a confirmed bullish technical breakout with notable insider buying and a solid earnings track record, but quality sitting well below the required floor and elevated short and put positioning keep this a speculative, binary biotech bet.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.6 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 9.1 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 7.1 |
- ▸Overbought (RSI 72)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 120%
Insider
8.7/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 8.0 |
| insider conviction | 8.0 |
| holder change | 10.0 |
- ▸Notable insider buying — $3,414,859 (0.350% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.4 |
| growth rank | 5.0 |
Technical
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.6 |
| support resistance | 2.7 |
| 52w position | 6.6 |
| gap | 6.0 |
Risk (lower is worse)
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 0.4 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 5.9 |
| max pain risk | 3.0 |
| beta | 6.3 |
| debt equity | 9.5 |
- ▸High short interest justified: 17%
- ▸Above max pain $1
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 6.7 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:7.9>=5.5
- ASYMMETRY:6.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:37d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
6.11
Upside
+91.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.0B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Insider at 8.7, and Momentum at 7.9; the weakest are Quality at 1.8, Peer rank at 3.7, and Technical at 4.2. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 6.11 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Notable Insider Buying
Trip ifInsider signal flips to bearish with net insider selling exceeding $1,000,000 in a rolling 90-day period.
- P2Quality Below Required Floor
Trip ifQuality score exceeds 4.0 from the current 1.8.
- P3Confirmed Breakout Momentum
Trip ifMomentum score falls below 3.0 from the current 6.6.
- P4Elevated Bearish Positioning
Trip ifShort interest falls below 8% of float.
- P5Solid Earnings Track Record
Trip ifEarnings beat rate falls below 50% over the next 4 reported quarters.